- Home
- FORA vs BEAT Comparison
FORA vs BEAT Comparison
Compare FORA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- BEAT
- Stock Information
- Founded
- FORA 2014
- BEAT 2015
- Country
- FORA United States
- BEAT United States
- Employees
- FORA N/A
- BEAT N/A
- Industry
- FORA Computer Software: Prepackaged Software
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- FORA Technology
- BEAT Technology
- Exchange
- FORA Nasdaq
- BEAT Nasdaq
- Market Cap
- FORA 62.7M
- BEAT 59.0M
- IPO Year
- FORA N/A
- BEAT 2021
- Fundamental
- Price
- FORA $2.06
- BEAT $1.70
- Analyst Decision
- FORA Strong Buy
- BEAT Buy
- Analyst Count
- FORA 1
- BEAT 1
- Target Price
- FORA $5.00
- BEAT $8.00
- AVG Volume (30 Days)
- FORA 6.9K
- BEAT 62.6K
- Earning Date
- FORA 06-06-2025
- BEAT 05-13-2025
- Dividend Yield
- FORA N/A
- BEAT N/A
- EPS Growth
- FORA N/A
- BEAT N/A
- EPS
- FORA N/A
- BEAT N/A
- Revenue
- FORA $22,332,001.00
- BEAT N/A
- Revenue This Year
- FORA $13.31
- BEAT N/A
- Revenue Next Year
- FORA N/A
- BEAT N/A
- P/E Ratio
- FORA N/A
- BEAT N/A
- Revenue Growth
- FORA 9.00
- BEAT N/A
- 52 Week Low
- FORA $1.85
- BEAT $1.45
- 52 Week High
- FORA $4.03
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- FORA 50.21
- BEAT 50.86
- Support Level
- FORA $1.92
- BEAT $1.50
- Resistance Level
- FORA $2.16
- BEAT $1.70
- Average True Range (ATR)
- FORA 0.12
- BEAT 0.11
- MACD
- FORA 0.00
- BEAT 0.01
- Stochastic Oscillator
- FORA 51.28
- BEAT 75.47
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.